Needham raised the firm’s price target on Hims & Hers (HIMS) to $35 from $30 and keeps a Buy rating on the shares. The company’s results came in below estimates and the management lowered its FY26 EBITDA outlook, though the firm remains bullish on the opportunity ahead as HIMS’ renewed partnership with Novo (NVO) is translating into strong early demand, with HIMS on track to add 100K new weight-loss subscribers per month, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Morning News Wrap-Up, 5/12/26: Today’s Biggest Stock Market Stories!
- Hims & Hers Health Stock (HIMS) Sinks on Dismal Q1 Earnings and Outlook; Here’s What Analysts Are Saying
- Morning Movers: Zebra surges and Under Armour plummets after Q1 results
- Video: GameStop slips after eBay turns down takeover offer
- Hims & Hers Health: Hold Maintained as Profitability Pressures Offset Growth; $21 Price Target Reiterated
